Swiss National Bank Grows Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Swiss National Bank grew its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMCGet Rating) by 5.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 139,500 shares of the biotechnology company’s stock after purchasing an additional 7,400 shares during the period. Swiss National Bank’s holdings in Blueprint Medicines were worth $7,046,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Van ECK Associates Corp lifted its holdings in shares of Blueprint Medicines by 16.0% during the first quarter. Van ECK Associates Corp now owns 1,548 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 213 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Blueprint Medicines by 50.7% during the second quarter. Nisa Investment Advisors LLC now owns 684 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 230 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Blueprint Medicines by 2.0% during the first quarter. Principal Financial Group Inc. now owns 17,019 shares of the biotechnology company’s stock valued at $1,087,000 after acquiring an additional 339 shares in the last quarter. Captrust Financial Advisors increased its position in shares of Blueprint Medicines by 2.5% during the first quarter. Captrust Financial Advisors now owns 16,206 shares of the biotechnology company’s stock valued at $1,035,000 after acquiring an additional 401 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC increased its position in shares of Blueprint Medicines by 414.2% during the first quarter. Steward Partners Investment Advisory LLC now owns 617 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 497 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on BPMC shares. SVB Leerink reduced their price target on shares of Blueprint Medicines from $57.00 to $52.00 and set a “market perform” rating for the company in a research report on Wednesday, November 2nd. Stifel Nicolaus lifted their target price on shares of Blueprint Medicines from $93.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, August 18th. Piper Sandler decreased their price target on shares of Blueprint Medicines from $65.00 to $59.00 in a research note on Tuesday, August 2nd. Jefferies Financial Group decreased their price target on shares of Blueprint Medicines from $84.00 to $80.00 in a research note on Wednesday, November 2nd. Finally, The Goldman Sachs Group decreased their price target on shares of Blueprint Medicines from $143.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, November 3rd. Two research analysts have rated the stock with a sell rating, six have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Blueprint Medicines presently has a consensus rating of “Hold” and a consensus target price of $83.67.

Insider Activity at Blueprint Medicines

In related news, insider Fouad Namouni sold 3,477 shares of the company’s stock in a transaction dated Tuesday, October 4th. The shares were sold at an average price of $67.30, for a total transaction of $234,002.10. Following the transaction, the insider now directly owns 52,797 shares in the company, valued at approximately $3,553,238.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Blueprint Medicines news, CEO Kate Haviland purchased 1,100 shares of the stock in a transaction dated Thursday, November 3rd. The stock was purchased at an average price of $43.98 per share, with a total value of $48,378.00. Following the transaction, the chief executive officer now owns 92,281 shares of the company’s stock, valued at $4,058,518.38. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Fouad Namouni sold 3,477 shares of the stock in a transaction that occurred on Tuesday, October 4th. The shares were sold at an average price of $67.30, for a total transaction of $234,002.10. Following the sale, the insider now directly owns 52,797 shares of the company’s stock, valued at approximately $3,553,238.10. The disclosure for this sale can be found here. 3.42% of the stock is currently owned by insiders.

Blueprint Medicines Stock Performance

Shares of NASDAQ:BPMC opened at $43.57 on Wednesday. The company has a market capitalization of $2.61 billion, a price-to-earnings ratio of -3.60 and a beta of 0.67. Blueprint Medicines Co. has a 12 month low of $40.78 and a 12 month high of $111.78. The firm’s 50-day moving average is $54.41 and its 200 day moving average is $57.69. The company has a current ratio of 6.99, a quick ratio of 6.79 and a debt-to-equity ratio of 0.19.

About Blueprint Medicines

(Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

Read More

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. (NASDAQ:BPMCGet Rating).

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.